FDA Approves First Drug for Myelofibrosis With Thrombocytopenia

Pacritinib is indicated specifically for patients with myelofibrosis and very low platelet counts, which develop in about one third of patients.
FDA Approvals

source https://www.medscape.com/viewarticle/969389?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost